Rhythm Pharmaceuticals Statistics
Total Valuation
RYTM has a market cap or net worth of $6.23 billion. The enterprise value is $5.96 billion.
Important Dates
The last earnings date was Thursday, February 26, 2026, before market open.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RYTM has 67.21 million shares outstanding. The number of shares has increased by 6.54% in one year.
| Current Share Class | 67.21M |
| Shares Outstanding | 67.21M |
| Shares Change (YoY) | +6.54% |
| Shares Change (QoQ) | +0.93% |
| Owned by Insiders (%) | 0.80% |
| Owned by Institutions (%) | 90.96% |
| Float | 53.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 32.84 |
| Forward PS | 20.91 |
| PB Ratio | 44.81 |
| P/TBV Ratio | 46.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 31.38 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.41, with a Debt / Equity ratio of 0.42.
| Current Ratio | 4.41 |
| Quick Ratio | 3.92 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.33 |
Financial Efficiency
Return on equity (ROE) is -90.45% and return on invested capital (ROIC) is -36.34%.
| Return on Equity (ROE) | -90.45% |
| Return on Assets (ROA) | -27.51% |
| Return on Invested Capital (ROIC) | -36.34% |
| Return on Capital Employed (ROCE) | -51.31% |
| Weighted Average Cost of Capital (WACC) | 15.45% |
| Revenue Per Employee | $670,519 |
| Profits Per Employee | -$713,488 |
| Employee Count | 283 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 0.88 |
Taxes
In the past 12 months, RYTM has paid $497,000 in taxes.
| Income Tax | 497,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +73.91% in the last 52 weeks. The beta is 2.04, so RYTM's price volatility has been higher than the market average.
| Beta (5Y) | 2.04 |
| 52-Week Price Change | +73.91% |
| 50-Day Moving Average | 104.47 |
| 200-Day Moving Average | 93.98 |
| Relative Strength Index (RSI) | 37.06 |
| Average Volume (20 Days) | 764,076 |
Short Selling Information
The latest short interest is 6.02 million, so 8.96% of the outstanding shares have been sold short.
| Short Interest | 6.02M |
| Short Previous Month | 6.24M |
| Short % of Shares Out | 8.96% |
| Short % of Float | 11.17% |
| Short Ratio (days to cover) | 10.39 |
Income Statement
In the last 12 months, RYTM had revenue of $189.76 million and -$201.92 million in losses. Loss per share was -$3.11.
| Revenue | 189.76M |
| Gross Profit | 170.27M |
| Operating Income | -192.02M |
| Pretax Income | -196.04M |
| Net Income | -201.92M |
| EBITDA | -190.59M |
| EBIT | -192.02M |
| Loss Per Share | -$3.11 |
Full Income StatementBalance Sheet
The company has $388.95 million in cash and $112.17 million in debt, with a net cash position of $276.78 million or $4.12 per share.
| Cash & Cash Equivalents | 388.95M |
| Total Debt | 112.17M |
| Net Cash | 276.78M |
| Net Cash Per Share | $4.12 |
| Equity (Book Value) | 270.03M |
| Book Value Per Share | 2.07 |
| Working Capital | 360.97M |
Full Balance SheetMargins
Gross margin is 89.73%, with operating and profit margins of -101.19% and -103.57%.
| Gross Margin | 89.73% |
| Operating Margin | -101.19% |
| Pretax Margin | -103.31% |
| Profit Margin | -103.57% |
| EBITDA Margin | -100.44% |
| EBIT Margin | -101.19% |
| FCF Margin | n/a |
Dividends & Yields
RYTM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.54% |
| Shareholder Yield | -6.54% |
| Earnings Yield | -3.24% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RYTM is $130.57, which is 40.81% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $130.57 |
| Price Target Difference | 40.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | 59.22% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |
